Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Spokane, WA

Spokane, Washington, United StatesNot linked to an institution yet

2running trials
0closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Active, not recruiting
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· Phase 2/3· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045· Phase 2/3· Source

Researchers

No researcher is linked here yet.

Site data: ClinicalTrials.govUpdated 11 Nov 2026

Report an error

Under construction, not live – Spokane, WA: trial site – Frontlight Research